S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Biden To Unleash "Choke Point" Operation On America? (Ad)
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Biden To Unleash "Choke Point" Operation On America? (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Biden To Unleash "Choke Point" Operation On America? (Ad)
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Biden To Unleash "Choke Point" Operation On America? (Ad)
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Biden To Unleash "Choke Point" Operation On America? (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Biden To Unleash "Choke Point" Operation On America? (Ad)
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Biden To Unleash "Choke Point" Operation On America? (Ad)
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Biden To Unleash "Choke Point" Operation On America? (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Biden To Unleash "Choke Point" Operation On America? (Ad)
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
S&P 500   3,971.27
DOW   32,394.25
QQQ   307.12
Walgreens Boots Alliance: Blue Chip, High-Yield Turnaround Story
Biden To Unleash "Choke Point" Operation On America? (Ad)
3 Small Financial Software Makers Showing Strong Chart Action
Roku And The 20% Rally That’s About To Start 
Biden To Unleash "Choke Point" Operation On America? (Ad)
Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data
Don't Be Fooled by These 3 Value Traps
Biden To Unleash "Choke Point" Operation On America? (Ad)
The Bottom Is In For McCormick & Company
Interactive Brokers: A Better Bet Than Schwab Post-SVB?
EPA:GNFT

Genfit - GNFT Stock Forecast, Price & News

€3.63
+0.01 (+0.28%)
(As of 03/28/2023 12:00 AM ET)
Add
Compare
Today's Range
€3.61
€3.66
50-Day Range
€3.62
€4.38
52-Week Range
N/A
Volume
37,265 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

GNFT stock logo

About Genfit (EPA:GNFT) Stock

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

GNFT Stock News Headlines

Genfit (EPA:GNFT) Trading Up 0.9%
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
GENFIT Reports Third Quarter 2022 Financial Information
A 100% Win Rate In 2022…
The next 10 minutes could change your life. We've recorded a special sit-down interview with a reclusive millionaire who details how he's closed out winning trade after winning trade throughout the volatility of 2022. In fact, he hasn't closed a single losing trade since 2016. Sounds impossible? It's not - and he'll prove it to you. pixel
GNFT Genfit S.A.
Genfit reports Q1 results
Genfit GAAP EPS of €1.23, revenue of €85.58M
GENFIT S.A. American Depositary Shares (GNFT)
Why Genfit Shares Are Rising
Pre-market Movers: GNFT, ABEO, SPRB, IO, CERN…
See More Headlines
Receive GNFT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Genfit and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
CIK
N/A
Fax
N/A
Employees
122
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Jean-Francois Mouney (Age 67)
    Co-Founder & Chairman
    Comp: $332.42k
  • Mr. M. Pascal Prigent (Age 54)
    Chief Exec. Officer
    Comp: $503.74k
  • Prof. Bart Staels (Age 59)
    Co-Founder & Chairman of the Scientific Advisory Board
  • Mr. Thomas Baetz (Age 48)
    Chief Financial Officer
  • Mr. Pascal Caisey (Age 54)
    Chief Operating Officer
  • Dr. Dean W. Hum Ph.D. (Age 60)
    Chief Scientific Officer
  • Mr. Laurent Lannoo (Age 52)
    Corp. Sec. & Director of Legal Affairs
  • Ms. Stefanie Magner (Age 41)
    Chief Compliance Officer & VP of International Legal Affairs
  • Ms. Emilie Desodt (Age 39)
    Vice-Pres of HR
  • Mr. Jean-Christophe Marcoux (Age 45)
    Chief Strategy Officer













GNFT Stock - Frequently Asked Questions

How have GNFT shares performed in 2023?

Genfit's stock was trading at €3.97 at the start of the year. Since then, GNFT stock has decreased by 8.7% and is now trading at €3.62.
View the best growth stocks for 2023 here
.

What other stocks do shareholders of Genfit own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Genfit investors own include Alimentation Couche-Tard (ATD.B), Aecon Group (ARE), Algonquin Power & Utilities (AQN), Aptiv (APTV), American Tower (AMT), Advanced Micro Devices (AMD), Ambarella (AMBA), Albemarle (ALB), Adobe (ADBE) and Abbott Laboratories (ABT).

What is Genfit's stock symbol?

Genfit trades on the EPA under the ticker symbol "GNFT."

What is Genfit's stock price today?

One share of GNFT stock can currently be purchased for approximately €3.62.

How many employees does Genfit have?

The company employs 122 workers across the globe.

How can I contact Genfit?

Genfit's mailing address is Parc Eurasante 885 avenue Eugene Avinee, Loos, Hauts De France 59120. The official website for the company is www.genfit.com. The company can be reached via phone at 33 3 20 16 40 00.

This page (EPA:GNFT) was last updated on 3/29/2023 by MarketBeat.com Staff